- Home
- LDTC vs PRPO Comparison
LDTC vs PRPO Comparison
Compare LDTC & PRPO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LDTC
- PRPO
- Stock Information
- Founded
- LDTC 2007
- PRPO N/A
- Country
- LDTC Canada
- PRPO United States
- Employees
- LDTC N/A
- PRPO N/A
- Industry
- LDTC Blank Checks
- PRPO Biotechnology: Laboratory Analytical Instruments
- Sector
- LDTC Finance
- PRPO Industrials
- Exchange
- LDTC Nasdaq
- PRPO Nasdaq
- Market Cap
- LDTC 10.6M
- PRPO 8.8M
- IPO Year
- LDTC N/A
- PRPO N/A
- Fundamental
- Price
- LDTC $1.17
- PRPO $6.51
- Analyst Decision
- LDTC Buy
- PRPO
- Analyst Count
- LDTC 2
- PRPO 0
- Target Price
- LDTC $3.00
- PRPO N/A
- AVG Volume (30 Days)
- LDTC 2.8M
- PRPO 8.3K
- Earning Date
- LDTC 12-18-2024
- PRPO 11-06-2024
- Dividend Yield
- LDTC N/A
- PRPO N/A
- EPS Growth
- LDTC N/A
- PRPO N/A
- EPS
- LDTC N/A
- PRPO N/A
- Revenue
- LDTC $353,686.00
- PRPO $17,411,000.00
- Revenue This Year
- LDTC $1,296.78
- PRPO $75.18
- Revenue Next Year
- LDTC $137.49
- PRPO N/A
- P/E Ratio
- LDTC N/A
- PRPO N/A
- Revenue Growth
- LDTC 141.86
- PRPO 31.31
- 52 Week Low
- LDTC $0.22
- PRPO $4.31
- 52 Week High
- LDTC $4.98
- PRPO $7.30
- Technical
- Relative Strength Index (RSI)
- LDTC 50.69
- PRPO 64.52
- Support Level
- LDTC $1.27
- PRPO $6.00
- Resistance Level
- LDTC $1.28
- PRPO $6.34
- Average True Range (ATR)
- LDTC 0.26
- PRPO 0.37
- MACD
- LDTC -0.06
- PRPO 0.09
- Stochastic Oscillator
- LDTC 14.85
- PRPO 100.00
About LDTC LeddarTech Holdings Inc.
LeddarTech Holdings Inc is a company that develops and provides comprehensive perception software solutions that enable the deployment of ADAS and autonomous driving (AD) applications. Its automotive-grade software applies AI and computer vision algorithms to generate accurate 3D models of the environment, allowing for decision-making and safer navigation.
About PRPO Precipio Inc.
Precipio Inc is a healthcare solutions company focused on cancer diagnostics. It focuses on addressing the problem of cancer misdiagnoses by developing solutions to mitigate the root causes of this problem in the form of diagnostic products, reagents and services. The company operates Clinical Laboratory Improvement Amendments laboratories in both the New Haven, Connecticut and Omaha, Nebraska locations providing essential blood cancer diagnostics to office-based oncologists in many states nationwide. It provides new technologies to the oncology diagnostic laboratory market in the form of HemeScreen and IV-Cell product offerings. The company generates the majority of its revenue from third-party payers.